Prime Highlights-
- Eli Lilly shares rose 4% after new trial data for retatrutide showed the drug’s 4 mg dose delivered roughly 19% weight loss, matching Zepbound’s highest dose.
- Analysts say the data positions retatrutide as a strong next-line option and could help Lilly extend its lead in the $200 billion-plus obesity market.
Key Facts-
- Lilly shares have gained 9% so far this year, while rival Novo Nordisk has fallen around 17% in the same period.
- Side effects from retatrutide increased at higher doses, though tolerability at the 4 mg level was broadly in line with existing treatments.
Background-
Eli Lilly shares climbed 4% on Monday after the company released fresh trial data for its next-generation obesity drug retatrutide, raising expectations that the drugmaker will hold and extend its grip on the fast-growing weight-loss market.
Lilly put forward results from two retatrutide trials at the American Diabetes Association meeting in New Orleans. One trial covered treatment-naive type 2 diabetes patients and the other focused on people living with obesity.
Investors took particular note of the 4 mg dose, which produced roughly 19% weight loss. That figure puts it on par with the highest dose of Zepbound, Lilly’s current top-selling obesity therapy.
Tolerability was broadly in line with existing treatments, with similar discontinuation rates and low levels of vomiting. Side effects did, however, increase at higher doses.
Citi analysts said the 4 mg dose data was strong enough that the drug could be positioned as a first-line treatment. They described retatrutide as the next step for patients who have already used Lilly’s tirzepatide without getting the desired results.
Lilly shares are up 9% so far this year, building on a strong 2025 rally. Rival Novo Nordisk, by contrast, has lost around 17% in the same period. Some analysts said retatrutide could start competing directly with Novo’s products as early as next year.
J.P. Morgan analyst Chris Schott said Lilly has what it needs to raise the standard of care in obesity treatment and sees the company pushing further ahead in a market worth over $200 billion.
RBC Capital Markets analyst Trung Huynh said Lilly’s obesity portfolio shows its lead over rivals is growing, not shrinking.
Lilly also shared data on other pipeline candidates, including an approved weight-loss pill and an experimental injectable called eloralintide.